SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.
SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration
https://pubmed.ncbi.nlm.nih.gov/37247330/Actively Recruiting
Led by Angelina Passaro · Updated on 2026-05-22
150
Participants Needed
2
Research Sites
104 weeks
Total Duration
Researchers are investigating the response of triglyceride-rich lipoproteins and inflammatory cytokines after an Oral Fat Loading Test OFLT in people with type 2 diabetes T2D, prediabetes, and healthy controls. The study aims to understand if these responses can serve as early markers for the risk of diabetes progression and related complications. This observational cohort study includes three groups individuals with T2D, prediabetics, and control subjects. Participants will undergo the OFLT, which involves consuming a fat-rich, sugar-free mascarpone cream after a 12-hour fast. Blood samples are collected before and at 1, 2, 3, 4, and 6 hours after the fat intake to measure triglycerides, lipoproteins, cytokines, and other markers. The study includes a cross-sectional phase followed by a 36-month prospective follow-up to assess whether these biomarkers predict progression to diabetes, nephropathy, and major cardiovascular events. During the study, participants will have multiple blood draws to assess changes in triglyceride levels, lipoprotein particles, and inflammatory markers. Researchers will monitor progression from prediabetes to diabetes and the development of kidney and heart complications over three years. The main outcomes include triglyceride concentrations after OFLT and diabetes progression, with secondary measures including various lipoprotein and cytokine levels. Participants will be followed regularly to evaluate these markers and health outcomes.
CONDITIONS
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.
F
Fabiola Castaldo, Pharmacy
J
Juana M Sanz Molina, Chemistry
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Angelina Passaro
Lead Sponsor
University Hospital of Ferrara
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - One day
Participants undergo an Oral Fat Load Test involving a standardized fat meal followed by blood samples collected before and multiple times up to 6 hours after the test to measure triglyceride-rich lipoproteins and inflammatory cytokines.
1 visit (in-person) with blood samples collected before and at 1, 2, 3, 4, and 6 hours after the fat load
Duration - Up to 36 months
Participants are observed over a 36-month follow-up period to evaluate the progression to diabetes and development of complications.
Periodic assessments during follow-up (visit schedule depends on clinical practice)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration
https://pubmed.ncbi.nlm.nih.gov/37247330/Changting Xiao, Satya Dash, Cecilia Morgantini...
https://pubmed.ncbi.nlm.nih.gov/26106188/Katherine Ogurtsova, Leonor Guariguata, Noël C Barengo...
https://pubmed.ncbi.nlm.nih.gov/34883189/S M Grundy
https://pubmed.ncbi.nlm.nih.gov/8994405/Marius Carstensen, Claus Thomsen, Kjeld Hermansen
https://pubmed.ncbi.nlm.nih.gov/12898469/C A Whicher, S O'Neill, R I G Holt
https://pubmed.ncbi.nlm.nih.gov/31901175/Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima...
https://pubmed.ncbi.nlm.nih.gov/37762244/SCORE2 working group and ESC Cardiovascular risk collaboration
https://pubmed.ncbi.nlm.nih.gov/34120177/Petter Bjornstad, Robert H Eckel
https://pubmed.ncbi.nlm.nih.gov/30328521/Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima...
https://pubmed.ncbi.nlm.nih.gov/36362288/Angelina Passaro
Lead Sponsor
University Hospital of Ferrara
Collaborating Sponsor